Lessons from NKF-DOQIIron management

Seminars in Nephrology

Volumn 20, Issue 4, 2000, Pages 330-334

  Van Wyck, David B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

CHRONIC KIDNEY FAILURE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; IRON THERAPY; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0033943797     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/SNEP.2000.6474     Document Type: Article

References (27)

1. Ali MM, Fayemi MO, Rigolosi MR, et al: Hemosiderosis in hemodialysis patients. J Am Med Assoc 244:343-345, 1980
2. Hakim RM, Stivelman JC, Schulman G, et al: Iron over-load and mobilization in long-term hemodialysis patients. Kidney Int 10:293-299, 1990
3. Baker MLRI, Brozovic BB, Cattell WR, et al: Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine. Clin Nephrol 6:326-328, 1976
4. Eijgenraam FJ, Donckerwolcke RA: Treatment of iron overload in children and adolescents on chronic haemodialysis. Eur J Pediatr 149:359-362, 1990
5. Pitts TO, Barbour GL: Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron 22:316-321, 1978
6. Van Wyck DB, Stivelman JC, Ruiz J, et al: Iron status in patients receiving erythropoietin for dialysis- associated anemia. Kidney Int 35:712-716, 1989
7. Macdougall IC, Hutton RD, Cavill I, et al: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299:157-158, 1989
8. Drueke TB, Barany P, Cazzola M, et al: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 48:1-8, 1997
9. Wingard RL, Parker RA, Ismail N, et al: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995
10. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44:238-240, 1995
11. Sunder-Plassmann G, Horl WH: Erythropoietin and iron. Clin Nephrol 47:141-157, 1997
12. Fudin R, Jaichenko J, Shostak A, et al: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79:299-305, 1998
13. Markowitz GS, Kahn GA, Feingold RE, et al: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48:34-40, 1997
14. Ahsan N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dial-ysis patients: A single center comparative study. J Am Soc Nephrol 664-668, 1998
15. Ponka P: Cellular iron metabolism. Kidney Int 69:52-11, 1999 (suppl)
16. Huebers HA, Finch CA: The physiology of transferrin and transferrin receptors. Physiol Rev 67:520-582, 1987
17. Van Wyck DB: Efficacy and adverse effects of oral iron supplements. Semin Dialysis 12:235-236, 1999
18. Hoen B, Paul-Dauphin A, Hestin D, et al: EPIBAC-DIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876, 1998
19. Meyers DG: The iron hypothesis - Does iron cause atherosclerosis? Clin Cardiol 19:925-929, 1996
20. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low Hct values in patients with cardiac disease who are receiving hemodialysis and rHuEPO. N Engl J Med 339:584-590, 1998
21. Niederau MC, Fischer MR, Sonnenberg MA, et al: Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256-1262, 1985
22. Fishbane S, Ungureanu VD, Maesaka JK, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
23. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565-568, 1997
24. Allen DA, Breen C, Yagoob MM, et al: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNFα. J Invest Med 47:204-211, 1999
25. Tarng DC, Wei YH, Huang TP, et al: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55:2477-2486, 1999
26. Tarng DC, Huang TP, Chen TW, et al: Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int 69:5107-5118, 1999 (suppl)
27. Eschbach JW, DeOreo P, Adamson J, et al: NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 30:5192-5240, 1997 (suppl)